For the quarter ending 2025-09-30, KURA made $20,750,000 in revenue. -$74,116,000 in net income. Net profit margin of -357.19%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 20,750,000 | 15,288,000 | 14,108,000 | 13,470,750 |
| Research and development | 67,908,000 | 62,785,000 | 55,973,000 | 42,491,750 |
| General and administrative | 32,839,000 | 25,169,000 | 22,835,000 | 19,277,750 |
| Total operating expenses | 100,747,000 | 87,954,000 | 78,808,000 | 61,769,500 |
| Loss from operations | -79,997,000 | -72,666,000 | -64,700,000 | -48,298,750 |
| Interest and other income | 6,274,000 | 6,935,000 | 7,879,000 | 5,712,250 |
| Interest expense | 393,000 | 391,000 | 382,000 | 404,750 |
| Total other income, net | 5,881,000 | 6,544,000 | 7,497,000 | 5,307,500 |
| Loss before income taxes | -74,116,000 | -66,122,000 | -57,203,000 | -42,991,250 |
| Income tax expense | - | - | 226,000 | 504,500 |
| Net loss | -74,116,000 | -66,122,000 | -57,429,000 | -43,495,750 |
| Unrealized gain (loss) on short-term investments | - | - | - | -508,750 |
| Comprehensive loss | - | - | - | -42,987,000 |
| Earnings per share, basic, total | -0.85 | -0.75 | -0.66 | -0.505 |
| Earnings per share, diluted, total | -0.85 | -0.75 | -0.66 | -0.505 |
| Weighted average number of shares outstanding, basic, total | 87,645,000 | 87,586,000 | 87,415,000 | 21,540,250 |
| Weighted average number of shares outstanding, diluted, total | 87,645,000 | 87,586,000 | 87,415,000 | 21,540,250 |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)